Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IS-free Treg-engineered Haplo-HCT in AML/MDS
NCT04678401Phase 1Recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jan 2021
- Primary completion
- Aug 2028
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of Treg-enriched donor cells in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (3 arms), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Dose-limiting toxicities at 30 days. Started Jan 2021; status: recruiting.
02
Drugs
Treg-enriched donor cells
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04678401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04678401.